Locations
San Carlos, CA, USA · Foster City, CA, USA
industry
Biotechnology
Size
201 - 1000 employees
Stage
IPO
founded in
2013
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, vax-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the xpresscfᵀᴹ cell-free protein synthesis platform, exclusively licensed from sutro biopharma, inc. Unlike conventional cell-based approaches, the company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
Something looks off?On-site & Remote